Advanced search
Publication Cover
Journal of Medical Economics Volume 23, 2020 - Issue 5
Submit an article Journal homepage
2,681
Views
17
CrossRef citations to date
0
Altmetric
Oncology

Treatment patterns and direct medical costs of metastatic colorectal cancer patients: a retrospective study of electronic medical records from urban China

Lin ShenDepartment of Clinical Oncology, Beijing Cancer Hospital, Beijing, China;
,
Qi LiDepartment of Oncology, Shanghai General Hospital, Shanghai, China; ORCID Iconhttp://orcid.org/0000-0003-2588-6541
ORCID Icon,
Wei WangDepartment of Oncology, The First People’s Hospital of Foshan, Foshan, Guangdong, China;
,
Lingjun ZhuDepartment of Oncology, Jiangsu Province Hospital, Nanjing, China;
,
Qingchuan ZhaoXijing Hospital, Fourth Military Medical University, Xi’an, China;
,
Yongzhan NieXijing Hospital, Fourth Military Medical University, Xi’an, China;
,
Bo ZhuInstitute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, China;
,
Dong MaDepartment of Oncology, Guangdong General Hospital, Guangzhou, Guangdong, China;
,
Xiaoyan LinDepartment of Medical Oncology, Fujian Medical University Union Hospital, Xiamen, Fujian, China;
,
Xiaohong CaiDepartment of Medical Oncology, Sichuan Cancer Hospital and Institute, Chengdu, Sichuan, China;
,
Weijia FangSchool of Medicine, The First Hospital of Zhejiang Province, Hangzhou, Zhejiang, China;
,
Cike PengHealth Economics and Outcomes Research, Eli Lilly and Company China Affiliate, Shanghai, China;
,
Yun ChenHealth Economics and Outcomes Research, Eli Lilly and Company China Affiliate, Shanghai, China;
,
Honghao FangReal World Insights, IQVIA, Shanghai, China;
,
Zheng YinReal World Insights, IQVIA, Beijing, China;
,
Hongyan LiHealth Economics and Outcomes Research, Eli Lilly and Company China Affiliate, Shanghai, China;
,
Ning WangHealth Economics and Outcomes Research, Eli Lilly and Company China Affiliate, Shanghai, China;
&
Ruihua XuSun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaCorrespondence[email protected]
 show all
Pages 456-463 | Received 04 Jul 2019, Accepted 06 Dec 2019, Published online: 13 Feb 2020

References

  • Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer [cited 2019 Jan 20]. Available from: https://gco.iarc.fr/today.
  • Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health 2018;6(5):e555–e567.
  • Yuan Y, Li MD, Hu HG, et al. Prognostic and survival analysis of 837 Chinese colorectal cancer patients. WJG. 2013;19(17):2650–2659.
  • Koo JH, Leong RWL, Ching J, et al. Knowledge of, attitudes toward, and barriers to participation of colorectal cancer screening tests in the Asia-Pacific region: a multicenter study. Gastrointest Endosc. 2012;76(1):126–135.
  • Leung DY, Chow KM, Lo SW, et al. Contributing factors to colorectal cancer screening among Chinese people: a review of quantitative studies. IJERPH. 2016;13(5):506.
  • Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics. CA Cancer J Clin. 2017;67(3):104–117.
  • American Cancer Society. Survival rates for colorectal cancer by stage. American Cancer Society [cited 2018 Nov 2]. Available from: https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html.
  • René A, Emir H, Luis César B. Evolution of neoadjuvant therapy for extended hepatic metastases–have we reached our (non-resectable) limit? J Surg Oncol. 2015;102(8):922–931.
  • Zhang Y, Chen Z, Li J. The current status of treatment for colorectal cancer in China: a systematic review. Medicine. 2017;96(40):e8242.
  • Hospital Authority of National Health and Family Planning Commission of the People′s Republic of China, Chinese Society of Oncology. Chinese protocol of diagnosis and treatment of colorectal cancer (2017 edition). Zhonghua Wai Ke Za Zhi. 2018;56(4):241–258.
  • Huang HY, Shi JF, Guo LW, et al. Expenditure and financial burden for the diagnosis and treatment of colorectal cancer in China: a hospital-based, multicenter, cross-sectional survey. Chin J Cancer 2017;36(8):41.
  • Liu CC, Huang HY, Shi JF. Economic burden of colorectal cancer in China from 1996 to 2015: a systematic review. Zhongguo Zhong Liu. 2017;26:859–867.
  • Li J, Qin S, Xu RH, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA 2018;319(24):2486.
  • Ueno H, Mochizuki H, Akagi Y, et al. Optimal colorectal cancer staging criteria in TNM classification. J Clin Oncol. 2012;30(13):1519–1526.
  • Adaptation of international guidelines for metastatic colorectal cancer: an Asian consensus. Clin Colorectal Cancer 2014;13(3):145–155.
  • Ranhua C, Shuai Z, Dedong M, et al. A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer. Med Oncol. 2015;32(1):325.
  • Volker H, Ludwig Fischer VW, Thomas D, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–1075.
  • Department of Medical Administration of the Ministry of Health of the People’s Republic of China. Chinese protocol of diagnosis and treatment colorectal cancer (2010 edition). Zhongguo Yi Xue Qian Yan Za Zhi. 2011;3(6):130–146.
  • Zhu LM, Zhao YZ, Ju HX, et al. Efficacy and safety of bevacizumab in Chinese patients with metastatic colorectal cancer. Asian Pac J Cancer Prev. 2014;15(16):6559–6564.
  • Abrams TA, Meyer G, Schrag D, et al. Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer. J Natl Cancer Inst. 2014;106(2):djt371–djt371.
  • Hess GP, Peter Feng W, David Q, et al. Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice. JOP. 2010;6(6):301–307.
  • Carlomagno C, Stefano AD, Rosanova M, et al. Multiple treatment lines and prognosis in metastatic colorectal cancer patients. Cancer Metastasis Rev. 2019;38(1–2):307–313.
  • Yoshino T, Arnold D, Taniguchi H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018;29(1):44–70.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.